Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Nina Galipeau"'
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-12 (2019)
Abstract Background The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Me
Externí odkaz:
https://doaj.org/article/a41a4921f0444c218266b7e94024fd8f
Autor:
Nina Galipeau, Brittany Klooster, Meaghan Krohe, Derek H. Tang, Dennis A. Revicki, David Cella
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-12 (2019)
Abstract Background Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. T
Externí odkaz:
https://doaj.org/article/91841a67a89a42e0abdb055e8b225bc4
Autor:
Meaghan Krohe, Yanni Hao, Roger E. Lamoureux, Nina Galipeau, Denise Globe, Catherine Foley, Iyar Mazar, Jeffrey Solomon, Alan L. Shields
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 2016, Iss 10, Pp 93-102 (2016)
Externí odkaz:
https://doaj.org/article/81a2de5e6d694135a6b56673a232b746
Autor:
Nina Galipeau, Dennis A. Revicki, Derek H. Tang, Brittany Klooster, Meaghan Krohe, David Cella
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-12 (2019)
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes
Background The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Measurement
Autor:
Meaghan Krohe, David Cella, Brittany Klooster, Nina Galipeau, Derek H. Tang, Dennis A. Revicki
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-12 (2019)
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes
Background Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. This study
Autor:
Jeffrey Solomon, Alan L. Shields, A. Yaworsky, Nina Galipeau, Leighann Litcher-Kelly, Jonathan Stokes, Roger E. Lamoureux, Diane M. Turner-Bowker
Publikováno v:
Value in Health. 21:839-842
Objective Evidence-based recommendations for the a priori estimation of sample size are needed for qualitative concept elicitation (CE) interview studies in clinical outcome assessment (COA) instrument development. Saturation is described as the poin
Autor:
Alan L. Shields, Susan Vallow, Nina Galipeau, Connor Volpi, Annette Yim, Sylvia Su, Roger E. Lamoureux, Patricia Brandt
Publikováno v:
Blood. 138:4654-4654
Background Myelodysplastic syndromes (MDS) are associated with the reduction in healthy blood cells produced in the bone marrow, which subsequently lead to a variety of symptoms. A review of existing patient-reported outcome (PRO) questionnaires used
Autor:
Steven V. Edelman, Alan L. Shields, Nina Galipeau, Terry A. Jacobson, Andrew Koren, Usha G. Mallya, Michael H. Davidson
Publikováno v:
The Patient
Introduction The National Lipid Association Statin Intolerance (SI) Panel recognized the need for better understanding of the patient SI experience. Objective The objective of this research was to develop a patient-reported outcome (PRO) questionnair
Autor:
Yanni Hao, Meaghan Krohe, Iyar Mazar, Nina Galipeau, Catherine Foley, Denise Globe, Diane M. Turner-Bowker, Alan L. Shields
Publikováno v:
Expert Review of Quality of Life in Cancer Care. 1:197-205
Patient-reported outcome (PRO) measures are used in clinical research and practice for the assessment of disease-related symptoms and impacts as well as treatment-related side effects, from the patient perspective. However, a systematic examination o
Autor:
Diane M. Turner-Bowker, Yanni Hao, Catherine Foley, Nina Galipeau, Iyar Mazar, Meaghan Krohe, Denise Globe, Alan L. Shields
Publikováno v:
Current medical research and opinion. 32(10)
As a means to measure quantifiable signs, symptoms, and impacts of a disease or its treatment, patient-reported outcome (PRO) instruments can be applied to numerous settings, including use in drug development to support labeling claims. This research